drugset / Trial / NCT06997029

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT06997029

Phase 1 Recruiting 234 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Timeline

Start
2025-08-01
Primary completion
2028-12-14
Completion
2028-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986500 Unknown
Background Fulvestrant Small molecule
Background Palbociclib Small molecule